SVB Leerink analyst doesn't expect cancer drug developed by Innovent and Lilly to be approved
Investors should expect to see fewer Food and Drug Administration approvals of copycat PD-L1 therapies after an advisory committee recommended against approving an experimental cancer drug, according to SVB Leerink analysts. The drug in question, sintilimab, is being developed by Innovent Biologics Inc. , a Chinese drug maker, and Eli Lilly & Co. . The FDA's Oncologic Drugs Advisory Committee on Thursday voted against approving the drug as a frontline non-small cell lung cancer treatment;... Читать дальше...